Open Access
Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
Marc Humbert,Richard Beasley,J. Ayres +2 more
- pp 425-434
About:
The article was published on 2017-01-01 and is currently open access. It has received 848 citations till now. The article focuses on the topics: Omalizumab.read more
Citations
More filters
Journal ArticleDOI
Omalizumab in patients with allergic (IgE-mediated) asthma and IgE/bodyweight combinations above those in the initially approved dosing table
TL;DR: The safety and PK/PD findings from this study are consistent with previous data, and supported the extension of the omalizumab dosing table to include those patients with higher IgE/bodyweight combinations.
Journal ArticleDOI
Four-year follow-up in children with moderate/severe uncontrolled asthma after withdrawal of a 1-year omalizumab treatment.
TL;DR: The hypothesis that treatment with omalizumab could potentially modify the natural course of asthma is generated, however, further studies are needed.
Journal ArticleDOI
Omalizumab decreased IgE-release and induced changes in cellular immunity in patients with allergic asthma
Gerald Hanf,I. Brachmann,Jörg Kleine-Tebbe,Joachim Seybold,Gert Kunkel,Norbert Suttorp,Oliver Noga +6 more
TL;DR: Omalizumab, a recombinant monoclonal anti‐immunoglobulin E (IgE) antibody, shows proven efficacy in the treatment of allergic diseases and a little is known about the immunological pathways affected by the decrease of circulating free IgE during omalIZumab treatment.
Journal ArticleDOI
Predictors of response to therapy with omalizumab in patients with severe allergic asthma - a real life study.
Maria Kallieri,Andriana I. Papaioannou,Evgenia Papathanasiou,Polyxeni Ntontsi,Spyridon Papiris,Stelios Loukides +5 more
TL;DR: Lower baseline FEV1 and higher IL-13 levels in induced sputum supernatant were predictors of response to omalizumab, and patients with higher baseline serum IgE levels, shorter disease duration and higher blood eosinophils might benefit from a more prolonged treatment before being characterized as non-responders.
Journal ArticleDOI
Real-life effectiveness of omalizumab in severe allergic asthma above the recommended dosing range criteria
Mark Hew,Andrew Gillman,Michael Sutherland,Peter A. B. Wark,J. Bowden,Michael Guo,Helen K. Reddel,Christine Jenkins,Guy B. Marks,Frank Thien,Janet Rimmer,Gregory Katsoulotos,Matthew C. Cook,Ian A. Yang,Constance H. Katelaris,Simon D. Bowler,David Langton,Craig Wright,Michael Bint,Veronica Yozghatlian,Scott Burgess,Pathmanathan Sivakumaran,Kwok Yan,Vicky Kritikos,Matthew J. Peters,Melissa Baraket,Ali Aminazad,Paul Robinson,Adam Jaffe,Heather Powell,John W. Upham,Vanessa M. McDonald,Peter G. Gibson +32 more
TL;DR: Omalizumab (Xolair) dosing in severe allergic asthma is based on serum IgE and bodyweight and about 62% of patients receiving government‐subsidized omalizuab are enrolled in the Australian Xolair Registry (AXR).
References
More filters
Journal ArticleDOI
Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials.
Elizabeth F. Juniper,Gordon H. Guyatt,Robert S. Epstein,Penelope J. Ferrie,Roman Jaeschke,T K Hiller +5 more
TL;DR: A questionnaire suitable for all adults with asthma and designed to be responsive to within subject change and therefore may be used as a measure of outcome in clinical trials in asthma is developed.
Allergy, rhinitis, other respiratory diseases Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
William W. Busse,Jonathan Corren,Bobby Q. Lanier,Margaret McAlary,Angel FowlerTaylor,Giovanni Della Cioppa,Niroo Gupta,Fort Worth +7 more
TL;DR: Omalizumab as discussed by the authors is a recombinant humanized anti-IgE mAb, which forms complexes with free IgE, blocking its interaction with mast cells and basophils.
Journal ArticleDOI
Proceedings of the ATS Workshop on Refractory Asthma Current Understanding, Recommendations, and Unanswered Questions
Sally E. Wenzel,John V. Fahy,Charles G. Irvin,Stephen P. Peters,Sheldon L. Spector,Stanley J. Szefler,Thomas B. Casale,Michelle M. Cloutier,Jack A. Elias,Mark C. Liu,Virginia Taggert +10 more
TL;DR: The proceedings of an American Thoracic Society (ATS)-sponsored workshop are hoped to serve as an aid to begin to define, understand, and manage these refractory patients.
Journal ArticleDOI
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics
Markus Solèr,J. Matz,Robert G. Townley,R. Buhl,J. O'Brien,Howard Fox,J. Thirlwell,N. Gupta,G. Della Cioppa +8 more
TL;DR: Results indicate that omalizumab therapy safely improves asthma control in allergic asthmatics who remain symptomatic despite regular use of inhaled corticosteroids and simultaneous reduction in Corticosteroid requirement.